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A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children 
with severe epilepsy, treated between 1987 and 1994. identified from a total population of 300 patients seen annually, in a 
tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were 
treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously. 
A Kaplan-Meier curve, applied to each of the two index drugs, indicated that 71 and 62% of patients would be expected 
to continue taking LTG or GVG, respectively after 40 months. Improved seizure control (2.50%) at the time of audit was 
seen in 65% of LTG and 58% of GVG patient treatments for all epilepsy syndromes, but there was a higher proportion of 
patients with generalized epilepsy improved by LTG (28/4 I, 68%) than that improved by GVG (8/20,40%), and only those 
with generalized epilepsy treated with LTG became seizure free (8/38, 21%). 
Similar proportions of patients discontinued LTG (16%) and GVG (15%) due to an adverse experience, but a higher 
proportion discontinued GVG (18%) compared with LTG (6%) because of lack of efficacy. 
This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe 
epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, 
which should enable more rational use of these two drugs in the paediatric population with epilepsy. 
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INTRODUCTION 
Lamotrigine (LTG) and vigabatrin (GVG) are in- 
creasingly being prescribed to treat children with 
severe epilepsy. Assessment of the clinical efficacy 
and safety of new antiepileptic drugs (AED), such 
as LTG and GVG in children using controlled clin- 
ical trials poses special problems’ and, to date, 
has provided limited useful information for appli- 
cation of use of these drugs in clinical, every- 
day, paediatric practice’. The aim of the present 
study was to characterize the relative efficacy and 
tolerability of two new AEDs, LTG and GVG, 
in the every-day, clinical practice of treating chil- 
dren with severe epilepsy, refractory to conventional 
therapy. 
PATIENTS AND METHODS 
A survey of LTG and GVG treatment was undertaken 
between September 1994 and February 1995 at the 
1059-l 31 l/97/060479 + 05 $12.00/O 
University of Wales College of Medicine, based on 
the case notes of patients treated by one of the au- 
thors, a consultant paediatric neurologist, working in 
a tertiary referral outpatient clinic at the University 
Hospital of Wales, Heath Park, Cardiff, in the UK. 
A cohort of 109 children, prescribed LTG and GVG 
between 1987 and 1994, was identified from patients 
seen for management of epilepsy over a period of 
7 years. Three hundred children are seen annually, 
but many individuals attended for most of the 7 years 
under review. It should be noted that this paediatric 
neurology clinic serves a population of two million 
in the south-west of Britain, including South Wales 
and south-west England. The identification of pa- 
tients prescribed LTG was comprehensive and the 
GVG subset comprised approximately 90% of the 
total population prescribed this drug. 
A pro forma, slightly modified from that previ- 
ously designed for use in a similar study of these two 
drugs in an adult population treated in Liverpoo13, 
was used to define demography, duration of ther- 
apy, dosage and concomitant AED therapy, adverse 
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Table 1: Demographic data. - 
Gender (M: F) 
Number of patient treatments (o/o) 
40; 39 47: 39 
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Duration of meatmem (months) 
Age (ye@ 
<6 
< f-13 
> 13 
Neurological dysfunction 
Learning disability 
Behavioural disturbance 
3.5 34 
37 43 
7 9 
50 (63) 57 (66) 
61 (77) 59 (6% 
31 (39) 29 (34) 
Table 2: Patient accountability. 
LTG GVG 
Fig. 1: Kaplan-Meier survival curves for time to withdraw 
from lamotrigine (LTG) or vigabatrin (GVG). Each 
Kaplan-Meier curve applies only to treatment with one or 
other of the two index drugs, LTG or GVG. 
Patient status 
Continuing 
(II = 79) (%) ()I = 86) (%) 
59 (75) 58 (6-O 
effects leading to discontinuation, epilepsy and 
seizure type and aetiology, pre-existing or associated 
neurological, intellectual and behavioural dysfunction 
and response of seizure control to treatment with LTG 
and/or GVG. Seizure control was evaluated by esti- 
mating the average, monthly seizure frequency over 
3 months before the introduction of LTG or GVG 
and for the last 3 months of treatment with the max- 
imal dose of the new drug. Data were initially ob- 
tained from hospital case notes, missing information 
being obtained from general practitioners, paediatri- 
cians and families, when necessary. The completed 
data record forms were checked, collated and en- 
tered onto a computerized database for further analy- 
sis, using summary statistics and the construction of 
a Kaplan-Meier survival curve. The Kaplan-Meier 
curves for LTG and GVG apply only to treatment 
with each of these two index drugs. 
Not contiuuing 20 
Due to adverse experience I3 
Lack of efficacy 5 
)I = number of patient treatments. 
(25) 28 (33) 
(16) 13 (15) 
(6) 15 (18) 
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Fig. 2: Seizure control according to seizure reduction and 
epilepsy syndrome. n , LTG; q , GVG. 
RESULTS 
and 80 of the 86 patient treatments (93%) with GVG, 
had severe epilepsy, defined as more than one major 
seizure per month or more than one minor seizure 
per week. Patients were taking an average of two 
other AEDs when they commenced LTG or GVG and 
the majority had significant, pre-existing disorders, as 
outlined in Table 1. 
The database was derived from a total population 
of 300 patients treated annually for severe refrac- 
tory epilepsy in a tertiary referral centre. A subset of 
109 children was identified from the clinic’s database, 
who had been treated with add-on LTG and/or GVG. 
There were 79 patient treatments with LTG and 86 
with GVG. There were 42 patients who were treated 
with add-on LTG, 52 who were treated with add-on 
GVG and 20 who were treated with both drugs si- 
multaneously. Fifteen patients were treated with both 
drugs serially, 12 ending up on LTG and three con- 
tinuing to take GVG at the time of audit. 
The demographic data are shown in Table 1. The 
age and gender distribution and pattern of associated 
cerebral dysfunction were similar for the population 
subset treated with LTG and GVG. Almost all pa- 
tients, 78 of the 79 patient treatments (99%) with LTG 
It was estimated from the Kaplan-Meier curve 
that 71 and 62% of patients would be expected 
to continue taking LTG or GVG, respectively after 
40 months (Fig. 1). Improvement in seizure control 
by 50% or more, at the time of the audit, was seen 
in 65% of LTG patient treatments and in 58% of 
GVG patient treatments, for all epilepsy syndromes 
(Fig. 2). There was similar improvement in seizure 
control, associated with treatment with both drugs, in 
patients with localization-related epilepsy syndromes, 
but there was a higher proportion of patients with gen- 
eralized epilepsy improved by LTG, compared with 
that improved by GVG (Fig. 2). There was also a 
higher percentage of patient treatments with LTG 
(16%), compared with those with GVG (lo%), in 
which patients became seizure free (Fig. 3). It can 
be seen from this figure that only patients on LTG 
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DISCUSSION 
Data concerning the efficacy of new AED therapy in 
children are limited*, necessitating the use of com- 
parative efficacy studies in adults to enable a criti- 
cal selection of the appropriate AED to treat child- 
hood seizures’. It is also recognized that AED ther- 
apy in children must strike a reasonable therapeu- 
tic cost/benefit ratio*. There are a number of spe- 
cific childhood epilepsy syndromes, such as West 
syndrome, Lennox-Gastaut syndrome, myoclonic- 
astatic epilepsy, epilepsy with myoclonic absences 
and epilepsy syndromes associated with tuberous 
sclerosis, which can prove to be relatively refractory 
to conventional AEDs. A number of new AEDs have 
recently completed investigational trials in adults and 
have achieved registration for prescription in adults 
in a number of countries. Some of these investiga- 
tional agents, such as GVG, LTG arid gabapentin have 
been used with caution in children, mostly as part of 
compassionate-use programmes, with the publication 
of results of only a few open, uncontrolled trials’. 
The present survey of the initially add-on use 
of two new AEDs, LTG and GVG, in a relatively 
large tertiary referral outpatient population of chil- 
dren with severe epilepsy was retrospective and non- 
randomized, as was the survey previously carried out 
on both these drugs in adults3. A number of poten- 
tial systematic biases may have influenced the results 
and conclusions, including patient selection biases, 
such as the earlier introduction of GVG, resulting 
in the use of LTG in a more therapeutically refrac- 
tory patient population and the apparent early avoid- 
ance of the use of GVG in patients with general- 
ized epilepsy syndromes. Furthermore, adverse event 
recording was unblinded in the present retrospective 
study, as in the previous study, thereby introducing a 
further potential bias in attributing unwanted effects 
to LTG or GVG. This study was comprehensive, as 
far as the inclusion of all patients taking LTG, and 
included approximately 90% of all patients taking 
GVG. The retention times for both drugs were of rea- 
sonable duration, consistent with informative patterns 
of responsiveness and adverse events. The survey was 
that of a refractory paediatric population with severe 
epilepsy, as demonstrated by the pre-treatment seizure 
frequency, the relatively high incidence of associated 
neurological and intellectual impairment and by the 
concomitant intake of at least two other AEDs when 
the patients were started on LTG or GVG. 
The present study suggests that LTG is as effec- 
tive as GVG for the control or partial seizures in 
children and supports a different spectrum of efficacy 
for LTG and GVG, suggesting that LTG is a broad- 
spectrum agent, effective for both localization-related 
and generalized epilepsy syndromes, whereas GVG 
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Fig. 3: Seizure control according to being seizure free and 
epilepsy syndrome. w, LTG; q , GVG. 
with generalized epilepsy became seizure free and 
that there was a higher proportion of patients on 
GVG with localization-related epilepsy, who became 
seizure free (Fig. 3). Patient accountability, with re- 
spect to continuation of LTG or GVG and the rea- 
sons for discontinuing the audited drug, are shown in 
Table 2, from which it is evident that similar propor- 
tions of patients discontinued both drugs due to an 
adverse experience (Table 3) but there was a higher 
proportion of patients who discontinued GVG, com- 
pared with LTG, due to lack of efficacy. The seizure 
response of patients with special paediatric epilepsy 
syndromes is shown in Table 4. The therapeutic re- 
sponse of patients with Lennox-Gastaut syndrome to 
LTG and GVG and of patients with myoclonic-astatic 
epilepsy and with epilepsy with myoclonic absences 
is worth noting. 
Table 5 indicates the relevant LTG and GVG daily 
dose ranges. The mean plasma LTG level of pa- 
tients who responded with a 50% or more decrease in 
seizure frequency was 26.5 pmol/l (6.6 mg/l), with a 
95% confidence interval of O-53 pmol/l (O-13 mg/l), 
compared with non-responders, in whom the mean 
plasma LTG level was 18.4 pmol/l (4.6 mg/l), with 
a 95% confidence interval of -541 pmol/l (-l- 
10 mg/l). There was a trend for the plasma LTG 
concentration to be related to maximal daily dose, 
expressed as mglkglday, in patients who did not take 
concomitant sodium valproate (VPA). The value for 
the correlation between the plasma LTG level and 
dose factored for weight, in the 51 patients in whom 
it was measured, was 2.3164 (r2 = 5.3657). Vi- 
sual plotting of plasma LTG level vs. dose, factored 
for weight, demonstrated a better correlation for pa- 
tients not receiving VPA (r = 5.3645, r2 = 28.7779, 
n = 28) than for the total group, including those on 
VPA (r = 2.3164, r* = 5.3657). There was no obvi- 
ous correlation between the plasma LTG concentra- 
tion and seizure control, or between the plasma LTG 
concentration and the number of patients discontinued 
because of adverse experiences. 
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Table 3: Adverse experiences leading to withdrawal. 
Number of events (o/o) 
LTG treated patients 
(n = 79) 
n (%) 
Aggressive behaviour 0 (0) 
Seizure aggravation 7 (9) 
Rash 6 (7) 
Drowsiness 0 (0) 
Number leading to withdrawal (%) 
GVG treated patients 
(n = 86) 
n (%) 
8 (9) 
4 (5) 
0 (0) 
1 (1) 
Total 13 (16) 13 (15) 
Table 4: Therapeutic response of special epilepsy syndromes (~50% decrease in seizures). 
LTG GVG 
Special epilepsy syndrome (%) (%I 
Lennox-Gastaut syndrome (one seizure free) (47) 6/l; (50) 
Myoclonic-Astatic epilepsy (two seizure free) 719 
Epilepsy with myoclonic absences (two seizure free) 515 
Tuberous sclerosis associated epilepsy syndrome 213 
Severe myoclonic epilepsy of infancy 213 
Benign epilepsy of childhood with centrotemporal spikes, ‘plus’ (one 212 
seizure free) 
Batten’s late infantile syndrome l/l 
Absence epilepsy of childhood 111 
Neurofibromatosis, Type I - 
Mesial temporal sclerosis - 
Tumours, including: one probable DNET* and one - 
( 
(78) 014 (0) 
100) - - 
(67) 416 (67) 
(67) - - 
100) O/I (0) 
100) - - 
100) - - 
- 111 (IW 
- 212 (100) 
- 212 (100) 
medulloblastoma (1 seizure free) 
n = number of patients. 
*Dysplastic neuro-ectodermal tumour. 
Table 5: Maximal daily dose of LTG or GVG. 
Mean 
LTG GVG 
mglday wz/k~lday wzldv w/WW 
I17 (with VPA) 4.3 2387 72 
321 (without VPA) 10.0 
Median 100 (with VPA) 3.0 2000 71 
300 (without VPA) 9.0 
Range 3450 (with VPA) O-15 500-6000 16-169 
25-1200 (without VPA) 2-29 
should be selectively prescribed for .children with 
localization-related epilepsy, characterized by partial 
seizures. This phenomenon may have been reflected 
by the higher withdrawal rate of GVG compared with 
that of LTG, because of the lack of efficacy of GVG 
in children with generalized epilepsy syndromes. The 
pattern of therapeutic efficacy for LTG and GVG 
in children with specific epilepsy syndromes is of 
note. Both drugs appeared to provide reasonable ther- 
apeutic response in children with the Lennox-Gastaut 
syndrome and epilepsy syndromes associated with 
tuberous sclerosis, while LTG appeared to be particu- 
larly effective for treating myoclonic-astatic epilepsy, 
epilepsy with myoclonic absences, severe myoclonic 
epilepsy of infancy and benign epilepsy of childhood 
with centro-temporal spikes ‘plus’. LTG was also ef- 
fective in treating one child with Batten’s late in- 
fantile syndrome and one with absence epilepsy of 
childhood, while GVG, as expected, was associated 
with a 50% or greater seizure decrease in two chil- 
dren with mesial temporal sclerosis, two children with 
intra-cerebral tumours and one child with neurofibro- 
matosis Type 1. 
The overall prevalence of adverse experiences, re- 
sulting in discontinuation of LTG and GVG, was sim- 
ilar for both drugs. However, the type of adverse ex- 
perience leading to withdrawal was characterized by 
a drug hypersensitivity skin rash and seizure aggra- 
vation in children treated with LTG, compared with 
aggressive behaviour and, to a lesser extent, seizure 
aggravation in children treated with GVG. Overall, 
both new AEDs were well tolerated. 
The plasma LTG concentration was measured at 
maximal dose in two-thirds of children treated with 
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this drug. There was a trend for the plasma LTG con- 
centration to be related to maximal daily dose, in the 
absence of concomitant VPA therapy, However, there 
was no apparent relationship between plasma LTG 
concentration and either seizure control or discontin- 
uation because of adverse experiences. 
This study is not a substitute for randomized, con- 
trolled trials of LTG and GVG, but it does reflect the 
relative clinical effectiveness of these two AEDs in 
the real world of the treatment of children with severe 
epilepsy, refractory to previous treatment with con- 
ventional AEDs, as did a previous survey in adults3. 
Trials of new AEDs in children have been delayed 
until data about the drugs were available in adults’. 
Thus there have been relatively few controlled trials 
of LTG and GVG in children with severe epilepsy, 
to date. A clinical overview of data from five almost 
identical protocols provided information about the re- 
sults of treatment with LTG in 285 children with re- 
fractory epilepsy4. The report was related to three 
studies of LTG in children, including a single-blind 
study, a pharmacokinetic study and the study of a 
group receiving compassionate therapy. All the chil- 
dren, whose results were reviewed, received LTG as 
open, add-on therapy, with similar results and conclu- 
sions, compared with those found in the present study 
which, however, found a higher efficacy for seizure 
reduction with LTG, particularly for patients with 
localization-related epilepsy syndromes. It should be 
noted that this review4 included results of children as- 
sessed after the first 12 weeks of maintenance dosage. 
In a recently published evaluation of LTG treatment 
of childhood epilepsies, pooled data from five open, 
add-on studies indicated that it was efficacious in pa- 
tients with a broad range of seizure types, especially 
absence seizures and atonic seizures, and that it was 
well tolerated5. 
Similarly, there are relatively sparse data related 
to the therapeutic, cost/effective ratio of GVG for 
the treatment of children with epilepsy syndromes, 
refractory to conventional AED therapy2v6-*. There 
are a limited number of reports, comprising uncon- 
trolled observations on children with localization- 
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related syndromes and those with special epilepsy 
syndromes, such as Lennox-Gastaut syndromeg, West 
syndrome and epilepsy syndromes associated with 
tuberous sclerosis** lo* ’ ’ , treated as part of open, un- 
controllable therapeutic trials with GVG. The present 
retrospective survey of children with epilepsy syn- 
dromes refractory to conventional AEDs, chronically 
treated with LTG and GVG, thus serves to gener- 
ate hypotheses concerning the more rational use of 
these two drugs, which can subsequently be tested by 
prospective, controlled trials. 
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